Provided by Tiger Trade Technology Pte. Ltd.

Organon & Co

13.71
+0.01000.07%
Post-market: 13.720.0146+0.11%19:30 EDT
Volume:2.10M
Turnover:28.88M
Market Cap:3.60B
PE:17.29
High:13.74
Open:13.71
Low:13.71
Close:13.70
52wk High:13.79
52wk Low:5.69
Shares:262.60M
Float Shares:243.00M
Volume Ratio:1.13
T/O Rate:0.87%
Dividend:0.08
Dividend Rate:0.58%
EPS(TTM):0.7929
EPS(LYR):0.7200
ROE:24.04%
ROA:5.67%
PB:3.58
PE(LYR):19.04

Loading ...

Press Release: Organon Canada Announces the Appointment of Dominic BÉGIN as President and Managing Director

Dow Jones
·
Jul 22

NYSE Order Imbalance 314683.0 Shares on Buy Side

THOMSON REUTERS
·
Jul 21

Organon & Co - Complaint Filed July 6, 2026 Against Organon Board, Sun Pharma USA, Sun Pharma America- SEC Filing

THOMSON REUTERS
·
Jul 18

Organon & Co: Believes That Claims, Allegations in Complaint & Assertions in Pending Injunction Motion are Without Merit

THOMSON REUTERS
·
Jul 18

Press Release: Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

Dow Jones
·
Jul 16

Organon to Present New Pooled Phase 3 Analysis of VTAMA in Atopic Dermatitis at 2026 Pediatric Dermatology Meeting

Reuters
·
Jul 07

Jefferies Quarterly Profit Misses Estimates as Asset Management Weighs

Reuters
·
Jun 25

Jefferies Quarterly Profit More than Doubles on Dealmaking, Equities Strength

Reuters
·
Jun 25

Organon, Shanghai Henlius Biotech Launch Denosumab Biosimilars in Canada

MT Newswires Live
·
Jun 23

Organon Closes Deal to License Sebela Pharmaceuticals' Miudella Intrauterine Device

MT Newswires Live
·
Jun 22

Organon completes global MIUDELLA copper IUD licensing deal with Sebela

Reuters
·
Jun 22

Organon Completes Agreement to License Miudella®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device

THOMSON REUTERS
·
Jun 22

Organon & Co - Miudella Expected to Be Commercially Available in Late 2026

THOMSON REUTERS
·
Jun 22

Organon and Samsung Bioepis expand commercialization agreement for Pyzchiva

TIPRANKS
·
Jun 18

Organon, Samsung Bioepis expand Canada commercialization pact for ustekinumab biosimilar PYZCHIVA

Reuters
·
Jun 18

Organon & Co - Pyzchiva Expected to Launch in Canada in 2026

THOMSON REUTERS
·
Jun 18

Organon & Co - Agreement Expands Biosimilar Collaboration in Canada to Six Products

THOMSON REUTERS
·
Jun 18

Organon & Co - to Obtain Commercialization Rights to Pyzchiva in Canada

THOMSON REUTERS
·
Jun 18

Organon and Samsung Bioepis Expand Agreement to Commercialize Pyzchiva® (Ustekinumab), a Biosimilar Referencing Stelara® (Ustekinumab) in Canada

THOMSON REUTERS
·
Jun 18

Shore Capital Reaffirms Their Buy Rating on Origin Enterprises plc (OGN)

TIPRANKS
·
Jun 17